PIMREG and cancer: Hence, the directed inhibition of CatS with small molecule inhibitors could enhance the anti-tumor immune response in cancer, especially when targeting the TME and the relevant APC, i.e., primarily myeloid TAM and MDSC, and—depending on the tumor type—also B cells.